Bill > SB284

This bill establishes the Defense of Drug Delivery Act, which aims to protect covered entities participating in the federal 340B drug pricing program from manufacturer interference. The bill defines key terms such as "340B drug" (a discounted outpatient drug purchased by eligible healthcare providers) and "covered entity" (healthcare organizations like hospitals and clinics that qualify for the program). It prohibits manufacturers, third-party logistics providers, and repackagers from denying, restricting, or discriminating against the acquisition and delivery of 340B drugs to covered entities, and prevents these manufacturers from requiring additional health information or data beyond what is legally mandated. The attorney general is empowered to investigate potential violations and impose civil penalties of up to $50,000 per violation, with each package of 340B drugs constituting a separate violation. The state board of pharmacy can also investigate complaints and potentially discipline or revoke registrations of entities found in violation. The bill includes provisions that ensure compliance with federal laws, allows for limited drug distribution exceptions, and establishes a dedicated defense of drug delivery fund to support implementation and enforcement. Ultimately, the legislation seeks to protect healthcare providers' ability to access discounted drugs through the 340B program without undue restrictions from drug manufacturers.

Business and Industry

Federal and State Affairs (S)

https://kslegislature.gov/li/b2025_26/measures/sb284/